

28<sup>th</sup> December, 2021

The Dy. General Manager (Listing Dept.)  
BSE Limited,  
Corporate Relationship Dept.,  
1<sup>st</sup> Floor, New Trading Ring,  
P. J. Towers, Dalal Street, Fort,  
Mumbai - 400 001  
**(BSE Scrip Code: 500420)**

The Manager – Listing Dept.,  
National Stock Exchange of India Ltd.,  
Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No. C/1, G. Block,  
Bandra - Kurla Complex, Bandra (E),  
Mumbai – 400 051  
**(NSE Scrip Code: TORNTPHARM)**

Dear Sir,

**Sub.: Updated Press Release – Torrent Pharma to launch Molnupiravir under the brand name Molnutor® in India**

A press release issued by the Company with respect to captioned subject is attached for your information and record.

Thanking you,

Yours sincerely,

For TORRENT PHARMACEUTICALS LIMITED

MAHESH AGRAWAL  
VP (LEGAL) & COMPANY SECRETARY

---

**TORRENT PHARMACEUTICALS LIMITED**

CIN: L24230GJ1972PLC002126

Reg. Office : Torrent House, Off Ashram Road, Ahmedabad- 380 009, India. Phone: +91 79 26599000, Fax: +91 79 26582100,  
[www.torrentpharma.com](http://www.torrentpharma.com)

### **Torrent Pharma to launch Molnupiravir under the brand name Molnutor® in India**

Torrent Pharma has today announced that it is introducing MSD (a trade name of Merck & Co., Inc, Kenilworth, NJ, USA) and Ridgeback's molnupiravir under the brand name Molnutor® in India. Earlier this year, Torrent Pharma inked a non-exclusive voluntary licensing pact with MSD, granting rights to Torrent Pharma for manufacturing, distribution and marketing of Molnupiravir in more than 100 low-and middle-income markets including India for treatment of COVID-19.

The Drugs Controller General of India (DCGI), based on the review of clinical data of Molnupiravir has approved the drug for the treatment of COVID-19 in adults for restricted emergency use in India.

Molnupiravir is the oral antiviral approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and U.S. Food and Drug Administration (FDA) [for Emergency Use Authorisation (EUA)] for the treatment of mild-to-moderate COVID -19 in adults.

Commenting on the launch, Aman Mehta (Executive Director – India) said: “We are pleased to partner with MSD to bring Molnupiravir to patients across India. Molnupiravir will be an important addition to our healthcare system's ammunition in the fight against Covid-19.”

#### **About Torrent Pharmaceuticals Ltd:**

Torrent Pharma, with annual revenues of more than Rs 8,000 crores, is the flagship Company of the Torrent Group, with group revenues of more than Rs 20,000 crores. It is ranked 8<sup>th</sup> in the Indian Pharmaceuticals Market and is amongst the Top 5 in the therapeutics segments of Cardiovascular (CV), Central Nervous System (CNS), and Vitamins Minerals Nutritionals (VMN).

It is a specialty-focused company with 75%+ of its revenue in India from chronic & sub-chronic therapies. It has presence in 40 countries and is ranked No. 1 amongst the Indian pharma Companies in Brazil, Germany and Philippines. Torrent has 8 manufacturing facilities (7 in India & 1 in US), of which 5 are USFDA approved. With R&D as the backbone for its growth in domestic & overseas market, it has invested significantly in R&D capabilities with state-of-the-art R&D infrastructure employing around 750+ scientists.

In case of any enquiry / clarification, please contact Mr. Jayesh Desai on +91 9824501396

**TORRENT PHARMACEUTICALS LIMITED**

CIN : L24230GJ1972PLC002125

Reg.Office : Torrent House, Off Ashram Road, Ahmedabad - 380 009, India. Phone: +91 79 26599000, Fax: +91 79 26582100, [www.torrentpharma.com](http://www.torrentpharma.com)